SEARCH:   Advanced

Blood, 15 January 2005, Vol. 105, No. 2, pp. 548-551. Prepublished online as a Blood First Edition Paper on September 14, 2004; DOI 10.1182/blood-2004-03-1000. This Article Full Text (PDF) All Versions of this Article: 2004-03-1000v1 105/2/548    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Remberger, M. Articles by Ringden, O. Search for Related Content PubMed PubMed Citation Articles by Remberger, M. Articles by Ringden, O. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 17, 2004 Accepted September 1, 2004 Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors Mats Remberger*, Dietrich W Beelen, Axel Fauser, Nadezda Basara, Oliver Basu, and Olle Ringden Department of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Stockholm, Sweden Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany Clinic of BMT, Haematology and Oncology, Idar-Oberstein, Germany Department of Paediatric Haematology, Oncology and Oncology, University Hospital Essen, Essen, Germany * Corresponding author; email: mats.remberger{at}labmed.ki.se. The long-term follow-up of a study including 214 patients receiving either peripheral blood stem cells (PBSC) or bone marrow from an HLA-A, -B and -DR-compatible unrelated donor is presented. Median follow-up were 4.4 (2.3-7.3) and 5.0 (0.7-8.4) years in the two groups, respectively. Cumulative incidence of overall chronic GVHD were similar in the two groups (78% vs. 71%), while extensive chronic GVHD was significantly more common in the PBSC group compared to the BM group (39% vs. 24%, p=0.03). The five-year transplant-related mortality (TRM) were 37% in the PBSC group and 35% in the BM controls (p=0.7) and overall survival were 42% in both groups. The relapse incidences were 26% and 27% in the two groups, respectively, resulting in a disease-free survival of 41% in both groups. In conclusion, PBSC from HLA-compatible unrelated donors results in similar outcome compared to BM, but imply an increased risk for extensive chronic GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Fujii, G. Cuvelier, K. She, S. Aslanian, H. Shimizu, A. Kariminia, M. Krailo, Z. Chen, R. McMaster, A. Bergman, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group Blood, March 15, 2008; 111(6): 3276 - 3285. [Abstract] [Full Text] [PDF] H. C. Fung, M. A. Higman, and K. van Besien Stem cell transplantation ASH Self-Assessment Program, January 1, 2007; 2007(1): 328 - 360. [Full Text] [PDF] S. J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood, June 1, 2005; 105(11): 4200 - 4206. [Abstract] [Full Text] [PDF] H. J. Deeg Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) Hematology, January 1, 2005; 2005(1): 167 - 173. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020